Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGL-1 targeting peptide
- Development stage
- Preclinical
- Lead developer
- Fox Chase Cancer Center
- Modality
- Peptides
- Administration
- Intratumoral
01
Overview
The NGL-1 targeting peptide is a research-stage, functionally antagonistic small peptide designed to inhibit Netrin G1 Ligand (NGL-1, also known as LRRC4C). NGL-1 is a synaptic protein that is ectopically expressed in the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC), specifically on cancer-associated fibroblasts (CAFs) and immune cells such as myeloid and T cells. By targeting NGL-1, the peptide reduces the production of immunosuppressive cytokines and restores anti-tumor immune activity, effectively modulating the TME in a TGF-β-dependent manner. Research conducted at institutions like Fox Chase Cancer Center suggests that NGL-1 inhibition can phenocopy the effects of chemotherapy and improve survival in preclinical models of pancreatic cancer.
- Other names
- NGL-1 antagonist peptideNGL1 antagonist peptideNGL 1 antagonist peptideNetrin G1 Ligand targeting peptide
02
Targets
NGL-1 (Leucine-rich repeat-containing protein 4C)
Beyond the preview
Go deeper on NGL-1 targeting peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGL-1 targeting peptide.